Peer-influenced content. Sources you trust. No registration required. This is HCN.

FDA Approves Rubraca, First PARP Inhibitor for Prostate Cancer

Already approved to treat ovarian cancer, Rubraca (rucaparib) has been granted accelerated approval as the first PARP inhibitor to treat certain patients with prostate cancer, offering a completely new approach for physicians.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form